Arcellx, Inc. (ACLX) Reports Q4 Loss, Lags Revenue Estimates

Company Performance - Arcellx, Inc. reported a quarterly loss of $0.87 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.63, and a significant decline from earnings of $0.42 per share a year ago, indicating an earnings surprise of -38.10% [1] - The company posted revenues of $15.27 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 44.32%, and a decrease from year-ago revenues of $63.15 million [2] - Over the last four quarters, Arcellx has surpassed consensus EPS estimates three times, but has only topped consensus revenue estimates once [2] Stock Performance - Arcellx shares have declined approximately 21.4% since the beginning of the year, contrasting with the S&P 500's gain of 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.76 on revenues of $17.97 million, and for the current fiscal year, it is -$2.14 on revenues of $116.14 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Arcellx belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Arcellx's stock performance [5]